New antibody shows promise for Tough-to-Treat hodgkin lymphoma
NCT ID NCT05216835
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called AZD7789 in 45 people with classical Hodgkin lymphoma that had returned or not responded to at least two prior treatments. The drug is a special antibody designed to help the immune system fight cancer cells. The main goals were to check safety and find the right dose, while also looking at whether the drug could shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
45 people
The number who actually took part.
- Started
-
Mar 2022
- Finished
-
Sep 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
16 to 101 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * ≥ 16 years of age at the time of obtaining informed consent * Eastern Cooperative Oncology Group performance status of 0 or 1 at screening * At least one positron emission tomography (PET)-avid measurable lesion according to Modified Lugano Criteria after the last line of therapy. * Confirmed histological diagnosis of active relapse/refractory cHL * Failed at least 2 prior lines of systemic therapy. * No previous treatment with anti-TIM-3. * Adequate organ and bone marrow function * Non-pregnant women and willingness of female patients to avoid pregnancy or male participants willing to avoid fathering children through highly effective methods of contraception * Minimum body weight ≥ 40 kg for all participants. Exclusion Criteria: * Unresolved toxicities of ≥ Grade 2 from prior therapy * Any prior ≥ Grade 3 imAE while receiving prior checkpoint inhibitor immunotherapy * Patients with central nervous system (CNS) involvement or leptomeningeal disease. * History of allogeneic stem cell transplant or organ transplantation. * Any venous or arterial thromboembolic event within ≤ 6 months prior to the first dose of study intervention. * Active infection including Tuberculosis (TB), human immunodeficiency virus (HIV), hepatitis A, chronic or active hepatitis B, chronic or active hepatitis C, active COVID-19 infection * History of arrhythmia which is requires treatment, symptomatic or uncontrol led atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia * Uncontrolled intercurrent illness. * Active or prior documented pathologically confirmed autoimmune or inflammatory disorders. * Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active ILD * Other invasive malignancy within 2 years prior to screening * Congenital long QT syndrome or history of QT prolongation associated with other medications that cannot be changed or discontinued based on a cardiologist assessment * Current or prior use of immunosuppressive medication within 14 days prior to the first dose of study intervention * Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Relapsed or refractory classical Hodgkin lymphoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Duarte, California, 91010, United States
-
Research Site
Miami, Florida, 33136, United States
-
Research Site
Rochester, Minnesota, 55905, United States
-
Research Site
New York, New York, 10065, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Toronto, Ontario, M5G 1X6, Canada
-
Research Site
Montreal, Quebec, H3T 1E2, Canada
-
Research Site
København Ø, 2100, Denmark
-
Research Site
Lille, 59037, France
-
Research Site
Bologna, 40138, Italy
-
Research Site
Naples, 80131, Italy
-
Research Site
Valencia, 46010, Spain
-
Research Site
Manchester, M20 4BX, United Kingdom
-
Research Site
Oxford, 0X3 7LJ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.